Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.

Gonzalez VD, Falconer K, Michaëlsson J, Moll M, Reichard O, Alaeus A, Sandberg JK.

Clin Immunol. 2008 Jul;128(1):46-56. doi: 10.1016/j.clim.2008.03.521. Epub 2008 May 20.

PMID:
18495540
2.

Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.

Stegmann KA, Björkström NK, Veber H, Ciesek S, Riese P, Wiegand J, Hadem J, Suneetha PV, Jaroszewicz J, Wang C, Schlaphoff V, Fytili P, Cornberg M, Manns MP, Geffers R, Pietschmann T, Guzmán CA, Ljunggren HG, Wedemeyer H.

Gastroenterology. 2010 May;138(5):1885-97. doi: 10.1053/j.gastro.2010.01.051. Epub 2010 Feb 2.

PMID:
20334827
3.

Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.

Lee S, Watson MW, Flexman JP, Cheng W, Hammond T, Price P.

J Med Virol. 2010 Apr;82(4):568-74. doi: 10.1002/jmv.21742.

PMID:
20166183
4.

Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.

Gonzalez VD, Falconer K, Björkström NK, Blom KG, Weiland O, Ljunggren HG, Alaeus A, Sandberg JK.

J Immunol. 2009 Nov 15;183(10):6612-8. doi: 10.4049/jimmunol.0901437. Epub 2009 Oct 21.

5.

Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment.

Bozzano F, Picciotto A, Costa P, Marras F, Fazio V, Hirsch I, Olive D, Moretta L, De Maria A.

Eur J Immunol. 2011 Oct;41(10):2905-14. doi: 10.1002/eji.201041361.

6.

Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype.

Bhardwaj S, Ahmad F, Wedemeyer H, Cornberg M, Schulze Zur Wiesch J, van Lunzen J, Sarin SK, Schmidt RE, Meyer-Olson D.

Virol J. 2016 Apr 18;13:67. doi: 10.1186/s12985-016-0507-5.

7.

Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection.

Oliviero B, Mele D, Degasperi E, Aghemo A, Cremonesi E, Rumi MG, Tinelli C, Varchetta S, Mantovani S, Colombo M, Mondelli MU.

J Hepatol. 2013 Jul;59(1):38-44. doi: 10.1016/j.jhep.2013.03.003. Epub 2013 Mar 14.

PMID:
23499727
8.

Association of NKG2A with treatment for chronic hepatitis C virus infection.

Harrison RJ, Ettorre A, Little AM, Khakoo SI.

Clin Exp Immunol. 2010 Aug;161(2):306-14. doi: 10.1111/j.1365-2249.2010.04169.x. Epub 2010 Jun 9.

9.

Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection.

Anthony DD, Conry SJ, Medvik K, Sandhya Rani MR, Falck-Ytter Y, Blanton RE, Lederman MM, Rodriguez B, Landay AL, Sandberg JK.

J Infect Dis. 2012 Sep 15;206(6):969-73. doi: 10.1093/infdis/jis434. Epub 2012 Jul 10.

10.

Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment.

Dessouki O, Kamiya Y, Nagahama H, Tanaka M, Suzu S, Sasaki Y, Okada S.

Biochem Biophys Res Commun. 2010 Mar 5;393(2):331-7. doi: 10.1016/j.bbrc.2010.02.008. Epub 2010 Feb 6.

PMID:
20138830
11.

CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.

Lin AW, Gonzalez SA, Cunningham-Rundles S, Dorante G, Marshall S, Tignor A, Ha C, Jacobson IM, Talal AH.

Clin Exp Immunol. 2004 Aug;137(2):408-16.

12.

Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline.

Conry SJ, Meng Q, Hardy G, Yonkers NL, Sugalski JM, Hirsch A, Davitkov P, Compan A, Falck-Ytter Y, Blanton RE, Rodriguez B, Harding CV, Anthony DD.

J Infect Dis. 2012 Apr 1;205(7):1131-41. doi: 10.1093/infdis/jis027. Epub 2012 Feb 20.

14.

[Alteration of CD100 expression on natural killer cells in chronic patients with hepatitis C virus before and after initiation of antiviral treatment].

He Y, Li B, Zhou Y, Zhang Y, Guo Y, Ji G, Fan C, Jia Z.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014 Aug;30(8):856-60. Chinese.

PMID:
25108441
15.

CD56bright NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections.

Judge CJ, Kostadinova L, Sherman KE, Butt AA, Falck-Ytter Y, Funderburg NT, Landay AL, Lederman MM, Sieg SF, Sandberg JK, Anthony DD.

J Leukoc Biol. 2017 Jul;102(1):171-184. doi: 10.1189/jlb.5A1116-456R. Epub 2017 Apr 11.

16.

Chronic immune activation in the T cell compartment of HCV/HIV-1 co-infected patients.

Sandberg JK, Falconer K, Gonzalez VD.

Virulence. 2010 May-Jun;1(3):177-9. doi: 10.4161/viru.1.3.11206.

PMID:
21178437
17.

Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity.

Hu PF, Hultin LE, Hultin P, Hausner MA, Hirji K, Jewett A, Bonavida B, Detels R, Giorgi JV.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):331-40.

PMID:
7552495
18.

Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use.

Hotho DM, Kreefft K, Groothuismink ZM, Janssen HL, de Knegt RJ, Boonstra A.

Antiviral Res. 2013 Mar;97(3):347-55. doi: 10.1016/j.antiviral.2012.12.025. Epub 2013 Jan 2.

PMID:
23291200
20.

Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection.

Reiberger T, Rasoul-Rockenschaub S, Rieger A, Ferenci P, Gangl A, Peck-Radosavljevic M.

Eur J Clin Invest. 2008 Jun;38(6):421-9. doi: 10.1111/j.1365-2362.2008.01958.x.

PMID:
18489402

Supplemental Content

Support Center